Last reviewed · How we verify
STW5 (Iberogast, BAY98-7411)
STW5 is a herbal combination product that modulates gastric motility and secretion to improve digestive function and reduce functional gastrointestinal symptoms.
STW5 is a herbal combination product that modulates gastric motility and secretion to improve digestive function and reduce functional gastrointestinal symptoms. Used for Functional dyspepsia, Irritable bowel syndrome, Functional gastrointestinal disorders.
At a glance
| Generic name | STW5 (Iberogast, BAY98-7411) |
|---|---|
| Sponsor | Bayer |
| Drug class | Herbal combination product |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
STW5 (Iberogast) is a standardized herbal extract containing nine plant components that work through multiple mechanisms including enhancement of gastric muscle contractions, modulation of gastric acid secretion, and anti-inflammatory effects. The combination targets functional gastrointestinal disorders by improving gastric emptying and reducing visceral sensitivity, thereby alleviating symptoms such as abdominal pain, bloating, and dyspepsia.
Approved indications
- Functional dyspepsia
- Irritable bowel syndrome
- Functional gastrointestinal disorders
Common side effects
- Nausea
- Abdominal discomfort
- Diarrhea
- Headache
Key clinical trials
- A Pharmacy-based Study to Learn More About How Well Iberogast Works, How it Affects the Body, How it is Used, and User Satisfaction in Patients With Functional and Motility-related (Stomach and Bowel Movement-related) Gastrointestinal Diseases, Including Irritable Bowel Syndrome
- Study to Learn More About the Onset of Effect of Iberogast in Patients Suffering From Abnormal Stomach and Intestine Function
- Study in Patients Suffering From Heartburn and Backward Flow of Stomach Liquid Into the Esophagus (PHASE2)
- Efficacy/Safety Study to Confirm Iberogast's Efficacy in Patients With Irritable Bowel Syndrome Diagnosed on ROME III Criteria Compared to Placebo (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- STW5 (Iberogast, BAY98-7411) CI brief — competitive landscape report
- STW5 (Iberogast, BAY98-7411) updates RSS · CI watch RSS
- Bayer portfolio CI